hippocampus

SKF-83566 is a blood-brain permeable and orally active antagonist of D1-like dopamine receptor and a weaker competitive 5-HT2 receptor antagonist with Ki of 11 nM

Pradigastat (LCQ-908) is an orally active, potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor for the treatment of constipation, which may be used in the study of obesity and diabetes.

S 18986 is a selective, orally active, brain-penetrant positive allosteric modulator of AMPA-type receptors that enhances cognition in rodents by inducing the release of noradrenaline and acetylcholine in the rat hippocampus, subsequently improving object-recognition memory.

Repinotan (BAY x 3702 free base) is an orally active, selective 5-HT1A receptor agonist that crosses the blood-brain barrier (BBB), exhibits neuroprotective activity, counteracts morphine-induced depression of ventilation in anesthetized rats, and may be used in studies of acute ischemic stroke and traumatic brain injury.

Aripiprazole (OPC-14597) is an antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.

Gadoteridol (Gd-HP-DO3A) is a gadolinium-based MRI contrast agent that can be used for central nervous system imaging.

L-Allylglycine is an amino acid derivative that reduces glutamate decarboxylase (GAD) activity by 60% when administered at a dose of 39.8 μmol g per hour ex vivo in mouse brain preparations. L-Allylglycine (1.2 mmol kg, i.p.) induces convulsions and decreases GABA concentration throughout the cerebellum, pons, medulla, striatum, cortex, and hippocampus in mice. Chronic administration (3.2 μg 0.5 μl per hour for 13 days) of L-allylglycine in rats increases locomotor activity in an open field test and impairs attention in the 5-choice serial reaction time task (5CSRTT). In vitro, L-allylglycine inhibits GAD only when used at high concentrations (1-80 mM). The more potent in vivo activity can be attributed to metabolic conversion of L-allylglycine to 2-keto-4-pentanoic acid, a more potent convulsant and GAD inhibitor.

trans-Urocanic Acid ((E)-Urocanic acid), a compound predominantly distributed in the hippocampus and prefrontal cortex, is an isomer of cis-UCA, an epidermal UV-protectant, which enhances the stability of tenofovir eplerenomide in long-acting HIV applications. trans-Urocanic acid potently modulates immune trans-urocanic acid effectively modulates immune function, inhibits human natural killer cell activity in vitro, and can be used in Alzheimer's disease research.

Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

Tetrahydroxystilbene-2-O-β-D-glucoside (EH-201) is a low MW inducer of erythropoietin. Tetrahydroxystilbene-2-O-β-D-glucoside induces expression of erythropoietin, PPAR-γ coactivator 1α (PGC-1α) and haemoglobin in astrocytes and PC12 neuronal-like cells. In vivo, Tetrahydroxystilbene-2-O-β-D-glucoside treatment restores memory impairment, as assessed by the passive avoidance test, in SD, Aβ and KA mouse models. In the hippocampus of mice given Tetrahydroxystilbene-2-O-β-D-glucoside in their diet, levels of erythropoietin, PGC-1α and haemoglobin were increased. Treatment with Tetrahydroxystilbene-2-O-β-D-glucoside might be a therapeutic strategy for memory impairment in neurodegenerative disease, physiological ageing or traumatic brain injury.

L-803087 is a potent and selective agonist of the growth inhibitor sst4 receptor with a Ki value of 0.7 nM for sst4, demonstrating over 280-fold selectivity compared to other growth inhibitory receptors. L-803087 induces AMPA-mediated synaptic responses in the hippocampus in vitro and increases seizures in alginate-induced seizure-busting mice in vivo.

AR-A 2 is a selective 5-HT1B receptor antagonist with high affinity to guinea pig cortex 5-HT1B 1D and recombinant guinea pig 5-HT1B receptors (Ki: 0.24 and 0.47 nM), exhibiting a 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki: 5 nM).

Bifeprunox is a potent partial agonist of dopamine D2-like and 5-HT1A receptor (pEC50: 6.37 for hippocampus 5-HT1A; pKis: 7.19 and 8.83 for cortex 5-HT1A and striatum D2). It is an antipsychotic for the research of schizophrenia.

(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.

ZSET-845 is an enhancer of cognitive which enhances choline acetyltransferase activity in the hippocampus in the rat.

LuAF60097 is a high-affinity S2 receptor ligand that binds allosterically to the S1 site. This compound also acts as a serotonin transporter (SERT) inhibitor, as demonstrated by increased imipramine binding and elevated 5-HT (serotonin) levels in the hippocampus.

Lecozotan (SRA-333) is a potent and selective 5-HT antagonist developed for Alzheimer's disease treatment. This compound significantly increases the release of glutamate and acetylcholine in the hippocampus and dentate gyrus areas upon potassium ion stimulation, exhibiting cognitive enhancement properties. Long-term use of Lecozotan does not lead to tolerance or dysfunction of the 5-HT(1A) receptor, demonstrating its stable pharmacological properties. Additionally, acute administration can improve learning and memory abilities in rats without affecting their anxiety levels or behavior depression.

N-Stearoyltyrosine (N-(1-Oxooctadecyl)-L-tyrosine) is an analog of Anandamide. It exhibits neuroprotective effects by safeguarding the CA1 region of the hippocampus in a gerbil ischemia-reperfusion model. Additionally, N-Stearoyltyrosine inhibits free radical generation, enhances antioxidant capacity, and reduces IR-induced apoptosis (cell apoptosis).

ASM-IN-3 (Compound 21b) is a selective acid sphingomyelinase (ASM) inhibitor that can penetrate the blood-brain barrier, with an IC50 of 3.37 μM against purified human ASM. By inhibiting ASM activity in the hippocampus and promoting neurogenesis, ASM-IN-3 alleviates depressive-like behavior in reserpine-induced depressive rats.

SAM-315 (WAY-255315) is a potent antagonist of 5-Hydroxytryptamine-6 (5-HT6), with Ki and IC50 values of 1.1 nM and 4.6 nM, respectively. SAM-315 notably enhances the release of acetylcholine and glutamate in the hippocampus of the brain.

BNN27 is an agonist of the TrkA receptor (TrkAreceptor) and the p75NTR receptor (p75NTR receptor), exhibiting neurotrophic and anti-apoptotic properties. It enhances levels of glutamate, GABA, and glutamine in the hippocampus and prefrontal cortex of rats, improving glutamate turnover. In a mouse model of amyotrophic lateral sclerosis (ALS), BNN27 demonstrates neuroprotective effects, shows anti-inflammatory properties in an experimental autoimmune encephalomyelitis (EAE) model, and exhibits retinal protection in a rat diabetes model. BNN27 also possesses blood-brain barrier permeability.

VU10010 (VU 10010) is allosteric potentiator of M4 acetylcholine receptors.

UBP714 is a derivative of the NMDA receptor negative allosteric modulator UBP608. It also enhanced NMDAR mediated field EPSPs in the CA1 region of the hippocampus. UBP714 is a novel template for the development of potent and subunit selective NMDAR potent

NCFP is a mGlu5 positive allosteric modulator. It positively modulates mGlu5 without the induction of long-term potentiation and long-term depression in the hippocampus.